AG
KRTX

Artal Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Artal Group’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,747
Closed -$317K – 135
2023
Q1 		$317K Sell
1,747
-148,253
-99% -$28.4M 0.02% 109
2022
Q4 		$29.5M Buy
150,000
+25,000
+20% +$5.36M 1.65% 17
2022
Q3 		$28.1M Buy
+125,000
New +$25.3M 1.2% 25
2020
Q1 		– Sell
-50,000
Closed -$3.77M – 119
2019
Q4 		$3.77M Buy
+50,000
New +$2.19M 0.15% 83

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group's KRTX Position: Q2 2023 in Review

Artal Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 1,747 shares — an estimated $317K sold.

Artal Group first reported a position in KRTX in Q4 2019 and held it in 4 quarters. The position peaked at $29.5M in Q4 2022. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

  • Artal Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Artal Group sold 1,747 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $317K.
  • Artal Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Artal Group's Karuna Therapeutics, Inc. Common Stock position peaked at $29.5M in Q4 2022.
  • 289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.